Organic Active Ingredients TRIZ Cases

Heterocyclic sulfonyl substitution increases CB2 receptor selectivity over CB1, reducing central adverse events in cannabinoid agonist therapy.

ERK inhibitors occupy the ATP binding site to block kinase activity, addressing the lack of effective treatments for melanoma and other cancers.

Heterocyclic compounds inhibit cholesteryl ester transfer protein to elevate high-density lipoprotein cholesterol and reduce low-density lipoprotein levels.

An extended release implant activates the innate immune system to facilitate bone morphogenesis.

Pyrazole compounds substituted with heteroaryl groups inhibit SGLT1 activity, reducing osmotic diarrhea risk while treating diabetes.

Novel PI3K inhibitor compounds with specific molecular structures target distinct enzyme isoforms for therapeutic use.

Segmented 5-HT1A agonist dosing reduces serotonin syndrome risk by avoiding peak plasma concentrations while maintaining therapeutic efficacy.

C15-C19 hydrocarbon mixtures replace silicone oils in glycerol emulsions, reducing adhesion strength below 9 N without increasing formulation complexity.

A solid oral dosage form uses an inert tamper-resistant core surrounded by an active agent coating to provide high breaking strength.

Pharmacological inhibition of endothelial-to-mesenchymal transition prevents neointimal stenosis in cell-free tissue-engineered vascular grafts.

Crystallizing HIV prodrug with HPMC forms spherical agglomerates, resolving fragile needle structure and poor flow capability.

A multilayered oral dosage form uses superabsorbent material to trap controlled release microparticles in a hard gel upon crushing.

Enzymatic hydrolysis separates krill biomass into lipid fractions and protein precipitates, preserving bioactive compounds while preventing clogging.

A lecithin-based microemulsion system solubilizes nonpolar compounds in water using a composite surfactant blend.

Adjusting pH to 8.5 with a cosolvent reduces hydrolytic degradation while maintaining solubility.

Engineered virus-like particles encapsulate oligodeoxynucleotides to extend half-life and reduce liver toxicity in cancer therapy.

Neural stem cells deliver oncolytic adenoviruses to overcome poor viral penetration in brain cancer tumors.

Optimized HFO-1234ze(E) and ethanol carrier prevents API flocculation, enabling single-activation dose delivery.

Combining lurbinectedin transcription inhibition with atezolizumab PD-L1 blockade targets small cell lung cancer cells through dual mechanisms.

Terminal modifications enhance stability and reduce immunogenicity while maintaining high specificity for ZPI silencing.

Overexpressing mir-17~92 delays motor neuron degeneration by inhibiting PTEN monoubiquitination, extending lifespan in ALS models.

A non-aqueous pharmaceutical gel composition dissolves adapalene using specific hydrophilic solvents and co-solvents.

Na+/K+ ATPase inhibitors disrupt circulating tumor cell clusters into single cells, reducing metastasis-seeding ability by altering DNA methylation patterns.

A communication scheduler prioritizes real-time queues over non-real-time queues using channel quality indicators to manage transmission services.

Exon 7 deletion creates stable TNFR Delta7 protein that inactivates TNF-alpha while avoiding tuberculosis and heart failure side effects.

Dried Lactobacillus cells and boric acid in a carrier restore vaginal flora to inhibit pathogen growth without antibiotic side effects.

Solvent-free hydrazine monohydrate deacetylates 9-dihydro-13-acetylbaccatin III, eliminating strong bases to improve synthesis yield.

Merging 5-ASA and vitamin D3 synergistically blocks beta-catenin signaling, reducing therapeutic doses while avoiding systemic toxicity of NSAIDs.

Engineered variable regions enable rapid internalization of CD74-expressing tumor cells, resolving slow uptake limitations.

Metal organic framework shells encapsulate lipid nucleic acid complexes, preventing electrostatic bond breakage and aggregate formation at ambient temperatures.

A minoxidil formulation using a glycerin-based release composition mediates controlled dermal flux for sustained therapeutic action.

Polypropylene sulfide nanocarriers deliver therapeutic agents to target tissues, reducing parasitemia and cardiac inflammation while minimizing side effects.

Novel pyrone derivatives address incurable multiple sclerosis by modifying chemical structures to improve treatment effectiveness and reduce regimen complexity.

5-(hydroxyalkyl)-1-phenyl-1,2,4-triazole derivatives act as dual vasopressin V1a and V2 receptor antagonists.

Structured vitamin C, D, and zinc dosing prevents infection while managing adverse event risks via preliminary assessment.

Tricyclic amine compounds inhibit CDK2 to halt uncontrolled cell proliferation and restore sensitivity in resistant HER2+ breast tumors.

Tricyclic compounds selectively activate M4 receptors via allosteric binding, reducing peripheral side effects from non-specific activation.

Novel isoquinoline piperazine compounds bind selectively to the norepinephrine transporter.

Ibuprofen reduces cough frequency via cyclooxygenase inhibition, eliminating separate antitussive medications.

Hybrid compounds merge alendronate with hydrogen sulfide releasing groups to stimulate bone mineralization.

Fungal biotransformation introduces hydroxyl groups at the C-7 position of artemisinin to create functionalized derivatives.

Extended nucleic acid linkages stabilize guide RNAs against degradation while reducing immunogenicity in CRISPR applications.

Multi-functional inhibitors target the JAK-STAT pathway to resolve variable efficacy across patient subgroups.